Audentes Therapeutics (NASDAQ:BOLD) Stock Rating Upgraded by BidaskClub

Audentes Therapeutics (NASDAQ:BOLD) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Wednesday, December 20th.

Several other analysts also recently weighed in on the company. Bank of America restated a “buy” rating and issued a $33.00 price target (up previously from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. Raymond James Financial initiated coverage on Audentes Therapeutics in a research note on Thursday, October 12th. They issued a “market perform” rating on the stock. William Blair initiated coverage on Audentes Therapeutics in a research note on Tuesday, October 17th. They set an “outperform” rating and a $35.00 target price on the stock. BMO Capital Markets initiated coverage on Audentes Therapeutics in a research note on Tuesday, December 5th. They set an “outperform” rating and a $35.00 target price on the stock. Finally, ValuEngine downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $35.00.

Audentes Therapeutics (BOLD) traded up $1.30 on Wednesday, reaching $37.47. The company’s stock had a trading volume of 344,682 shares, compared to its average volume of 406,481. The company has a market cap of $1,079.87, a price-to-earnings ratio of -10.74 and a beta of -0.21. Audentes Therapeutics has a fifty-two week low of $13.90 and a fifty-two week high of $41.80.

Audentes Therapeutics (NASDAQ:BOLD) last posted its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.88). research analysts expect that Audentes Therapeutics will post -3.5 EPS for the current year.

In other Audentes Therapeutics news, Director Louis G. Lange sold 18,000 shares of the firm’s stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $30.88, for a total transaction of $555,840.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Mary Newman sold 10,000 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $26.84, for a total value of $268,400.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,000 shares of company stock worth $1,052,480. 47.30% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the business. Redmile Group LLC grew its position in shares of Audentes Therapeutics by 77.8% during the second quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock valued at $27,922,000 after purchasing an additional 638,780 shares in the last quarter. Jennison Associates LLC grew its position in shares of Audentes Therapeutics by 182.4% during the second quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock valued at $16,189,000 after purchasing an additional 546,617 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Audentes Therapeutics by 130.3% during the second quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after purchasing an additional 383,837 shares in the last quarter. Artal Group S.A. purchased a new position in shares of Audentes Therapeutics during the third quarter valued at about $5,602,000. Finally, State Street Corp grew its position in shares of Audentes Therapeutics by 231.6% during the second quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock valued at $4,234,000 after purchasing an additional 154,544 shares in the last quarter. 78.95% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Audentes Therapeutics (NASDAQ:BOLD) Stock Rating Upgraded by BidaskClub” was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.thelincolnianonline.com/2018/01/13/audentes-therapeutics-bold-stock-rating-upgraded-by-bidaskclub-updated-updated.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply